Table 2.
Relationship Between PRMT5 and Pathological Data of BC Patients
| Factor | PRMT5 | χ2–Value | P-value | ||
|---|---|---|---|---|---|
| High Expression (n=45) | Low Expression (n=35) | ||||
| Age | 0.001 | 0.978 | |||
| ≥51 years (n=41) | 23 (51.11) | 18 (51.43) | |||
| <51 years (n=39) | 22 (48.89) | 17 (48.57) | |||
| BMI (kg/m2) | 0.080 | 0.778 | |||
| ≥23 (n=42) | 23 (51.22) | 19 (54.29) | |||
| <23 (n=38) | 22 (48.79) | 16 (45.71) | |||
| Tumor size | 7.174 | 0.007 | |||
| ≥3cm (n=34) | 25 (55.56) | 9 (25.71) | |||
| < 3cm (n=46) | 20 (44.44) | 26 (74.29) | |||
| TNM staging | 18.67 | <0.001 | |||
| I–II stage (n=47) | 17 (37.78) | 30 (85.71) | |||
| III stage (n=33) | 28 (62.22) | 5 (14.29) | |||
| Differentiation | 23.37 | <0.001 | |||
| Low differentiation (n=51) | 39 (86.67) | 12 (34.29) | |||
| High + moderate differentiation (n=29) | 6 (13.33) | 23 (65.71) | |||
| Lymphatic metastasis | 8.061 | 0.005 | |||
| Metastasized (n=22) | 18 (40.00) | 4 (11.43) | |||
| Not metastasized (n=58) | 27 (60.00) | 31 (85.57) | |||